Go Pro
NASDAQ:TOI

Oncology Institute (TOI) Stock Price, News & Analysis

Oncology Institute logo
$4.86 -0.21 (-4.14%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$4.90 +0.04 (+0.91%)
As of 07/31/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Oncology Institute Stock (NASDAQ:TOI)

Advanced

Key Stats

Today's Range
$4.86
$5.25
50-Day Range
$4.23
$6.28
52-Week Range
$2.32
$6.67
Volume
1.00 million shs
Average Volume
1.89 million shs
Market Capitalization
$480.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Moderate Buy

Company Overview

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Oncology Institute Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

TOI MarketRank™: 

Oncology Institute scored higher than 79% of companies evaluated by MarketBeat, and ranked 139th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oncology Institute has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Oncology Institute has a consensus price target of $8.50, representing about 74.9% upside from its current price of $4.86.

  • Amount of Analyst Coverage

    Oncology Institute has only been the subject of 4 research reports in the past 90 days.

  • Read more about Oncology Institute's stock forecast and price target.
  • Earnings Growth

    Earnings for Oncology Institute are expected to grow in the coming year, from ($0.18) to ($0.12) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncology Institute is -13.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncology Institute is -13.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Oncology Institute's valuation and earnings.
  • Percentage of Shares Shorted

    7.70% of the float of Oncology Institute has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncology Institute has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oncology Institute has recently increased by 6.23%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Oncology Institute does not currently pay a dividend.

  • Dividend Growth

    Oncology Institute does not have a long track record of dividend growth.

  • News Sentiment

    Oncology Institute has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Oncology Institute this week, compared to 3 articles on an average week.
  • Search Interest

    Only 6 people have searched for TOI on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Oncology Institute to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $483,099.00 in company stock, which represents 0.1006% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Oncology Institute insiders have bought 382.91% more of their company's stock than they have sold. Specifically, they have bought $609,265.00 in company stock and sold $126,166.00 in company stock.

  • Percentage Held by Insiders

    4.40% of the stock of Oncology Institute is held by insiders.

  • Percentage Held by Institutions

    36.86% of the stock of Oncology Institute is held by institutions.

  • Read more about Oncology Institute's insider trading history.
Receive TOI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncology Institute and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TOI Stock News Headlines

ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.tc pixel
See More Headlines

TOI Stock Analysis - Frequently Asked Questions

Oncology Institute's stock was trading at $3.56 at the beginning of 2026. Since then, TOI stock has increased by 36.5% and is now trading at $4.86.

The Oncology Institute, Inc. (NASDAQ:TOI) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.05. The company earned $147.44 million during the quarter, compared to analyst estimates of $142.10 million.
Read the conference call transcript
.

Top institutional shareholders of Oncology Institute include Fermata Advisors LLC (0.01%). Insiders that own company stock include Jorey Chernett, Growth I LP M33, Daniel Virnich, Brad Hively, Yale Podnos, Robert Ross Carter, Mark L Pacala, Mohit Kaushal and Havencrest Healthcare Partners.
View institutional ownership trends
.

Shares of TOI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncology Institute investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), AppLovin (APP) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/07/2026
Today
8/02/2026
Next Earnings (Estimated)
8/06/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NASDAQ:TOI
CIK
1799191
Fax
N/A
Employees
660
Year Founded
2007

Price Target and Rating

High Price Target
$10.00
Low Price Target
$7.00
Potential Upside/Downside
+74.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.37)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$60.61 million
Net Margins
-7.42%
Pretax Margin
-8.00%
Return on Equity
N/A
Return on Assets
-24.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.47
Quick Ratio
1.17

Sales & Book Value

Annual Sales
$502.73 million
Price / Sales
0.96
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.16) per share
Price / Book
-30.38

Miscellaneous

Outstanding Shares
98,840,000
Free Float
94,490,000
Market Cap
$480.36 million
Optionable
Not Optionable
Beta
0.36

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:TOI) was last updated on 8/2/2026 by MarketBeat.com Staff.
From Our Partners